Quent Capital LLC Sells 3,232 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Quent Capital LLC decreased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 76.7% during the 4th quarter, HoldingsChannel reports. The fund owned 983 shares of the biotechnology company’s stock after selling 3,232 shares during the period. Quent Capital LLC’s holdings in United Therapeutics were worth $347,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of UTHR. Geode Capital Management LLC boosted its stake in shares of United Therapeutics by 4.3% during the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock valued at $391,459,000 after purchasing an additional 45,566 shares in the last quarter. FMR LLC boosted its position in United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares during the period. Pacer Advisors Inc. grew its holdings in United Therapeutics by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after acquiring an additional 30,931 shares during the last quarter. Janus Henderson Group PLC increased its position in United Therapeutics by 12.3% in the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock valued at $164,978,000 after acquiring an additional 50,409 shares during the period. Finally, Assetmark Inc. increased its position in United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after acquiring an additional 152,249 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on UTHR. HC Wainwright boosted their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $382.08.

Insiders Place Their Bets

In related news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at $13,485,785.60. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 121,864 shares of company stock worth $44,516,965. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Stock Up 2.2 %

NASDAQ:UTHR opened at $353.31 on Wednesday. United Therapeutics Co. has a twelve month low of $210.64 and a twelve month high of $417.82. The company has a fifty day moving average of $362.06 and a 200-day moving average of $358.24. The firm has a market capitalization of $15.78 billion, a P/E ratio of 15.52, a P/E/G ratio of 0.92 and a beta of 0.57.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.